丙型肝炎病毒直接作用抗病毒药物及其耐药研究进展

摘要

近年来,多种不同机制的丙型肝炎病毒(HCV)直接作用抗病毒(DAA)药物不断研发并进入临床试验,其中Boceprevir与Telaprevir的Ⅲ期临床研究结果已公布,有望于近年进入临床应用.DAA药物引发的耐药问题应受到重视.丙型肝炎病毒DAA药物研发取得了重要进展,国内研究方向应结合中国患者丙型肝炎病毒的基因型及宿主特点.%Reccntly directly acting antiviral agents against hepatitic C virus with different mechanisms have been developed and put into clinical trials. Especially, results of phase Ⅲ clinical trials of Boceprevir and Telaprevir have been published, and these two agents are to be approval for maketing in recent years. Also much attention has been paid on anti-viral resistance against direct acting amtiviral agents. Greal progresses have been made in field of direct acting antiviral agents against hepatitic C virus. Domestic studies in this area should take characteristics of virus and host of Chinese chronic hepatitis C into consideration.